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Abstract
Introduction: Endothelial dysfunction (ED) participates to atherogenesis associated to rheumatoid arthritis. We
recently reported increased arginase activity/expression in vessels from adjuvant-induced arthritis (AIA) rats. In the
present study, we investigated the effects of a curative treatment with the arginase inhibitor Nw-hydroxy-nor-L-
arginine (nor-NOHA) on vascular dysfunction in AIA rats.
Methods: AIA rats were treated with nor-NOHA (40 mg/kg/d, ip) for 21 days after the onset of arthritis. A group of
untreated AIA rats and a group of healthy rats served as controls. ED was assessed by the vasodilatory effect of
acetylcholine (Ach) on aortic rings. The role of superoxide anions, prostanoids, endothelium-derived hyperpolarizing
factor (EDHF) and nitric oxide synthase (NOS) pathway was studied. Plasma levels of IL-6 and vascular endothelial
growth factor (VEGF) were determined by ELISA kits. Arthritis severity was estimated by a clinical, radiological and
histological analysis.
Results: Nor-NOHA treatment fully restored the aortic response to Ach to that of healthy controls. The results
showed that this beneficial effect is mediated by an increase in NOS activity and EDHF and reduced superoxide
anion production as well as a decrease in the activity of cyclooxygenase (COX)-2, thromboxane and prostacyclins
synthases. In addition, nor-NOHA decreased IL-6 and VEGF plasma levels in AIA rats. By contrast, the treatment did
not modify arthritis severity in AIA rats.
Conclusions: The treatment with an arginase inhibitor has a potent effect on ED in AIA independently of the
severity of the disease. Our results suggest that this new pharmacological approach has the potential as a novel
add-on therapy in the treatment of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory disease characterized by articular and extra-
articular manifestations involving cardiovascular dis-
eases, which accounts for 30 to 50% of all deaths [1].
Recent studies showed that atherosclerosis lesions occur
earlier and have a more rapid evolution in RA patients
than in the general population [1]. Endothelial dysfunc-
tion is thought to be a key event in the development of
atherosclerosis and has been identified in patients with
RA, even in the early diagnosed arthritis [1]. It is gener-
ally defined as impaired endothelium-dependent
vasodilation to specific stimuli and characterized by an
imbalance between vasoconstriction and vasodilation
factors. Although the improvement of endothelial func-
tion is recognized as an important element of the global
management of RA patients [2], the precise pathophy-
siological mechanisms of endothelial dysfunction in RA
are still poorly understood.
Consistent with the findings in humans, a few studies
reported impaired endothelial function in the model of
adjuvant-induced arthritis (AIA) in rats. In this model,
endothelial dysfunction positively correlates with disease
activity [3]. However, data concerning the pathophysio-
logical features of endothelial dysfunction are scarce.
Previous studies reported that vessels from AIA rats
exhibited a deficiency in tetrahydrobiopterin (BH4), the
co-factor of nitric oxide synthase (NOS) [4] and
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overproduced superoxide anions (O2
-.) [4-6]. Surpris-
ingly, whether there is an impairment of the production
of endothelium-derived vasodilator factors, such as nitric
oxide (NO), prostacyclin (PGI2) and endothelium-
derived hyperpolarizing factor (EDHF) or of contractile
factors such as angiotensin-II (ANG-II), endothelin-1
(ET-1) and thromboxane A2 (TXA2) is not known.
Recently, we identified the vascular arginase upregula-
tion as a new interesting mechanism contributing to
endothelial dysfunction in AIA rats [3].
Arginase (EC 3.5.3.1) is a hydrolytic enzyme responsi-
ble for converting L-arginine to L-ornithine and urea.
Mammalian arginases exist in two distinct isoforms
(type I and type II), which have specific subcellular loca-
lizations and tissues distribution. Notably, both arginase
isoforms are expressed by endothelial and vascular
smooth muscle cells [7]. Because NOS and arginase use
L-arginine as a common substrate, arginase may down-
regulate NO biosynthesis by competing with NOS for L-
arginine degradation. Consistent with this hypothesis,
increased vascular arginase activity was reported in var-
ious animal models of cardiovascular diseases [8,9] and
a few studies demonstrated the benefits of a chronic
treatment with an arginase inhibitor for treating
endothelial dysfunction associated to hypertension
[3,10,11], diabetes [12], atherosclerosis [13] or ageing
[14]. These pharmacological data have been partly con-
firmed by the data obtained from the mouse strains
with genetic ablation of arginase expression. Although
mice lacking arginase I (Arg I -/-) die in the perinatal
period as a consequence of a non-functional urea cycle
[15], mice with homologous deletion of arginase II
expression (Arg II -/-) are viable, have high plasma levels
of arginine and exhibit an enhanced vasorelaxation to
acetylcholine [16]. In the AIA model, we found that
increased arginase activity/expression correlated with
arthritis severity [3]. Moreover, our data suggested, at
least in vitro, that the upregulation of arginase contri-
butes to endothelial dysfunction likely by limiting the L-
arginine availability for NOS [3]. However, whether the
treatment with an arginase inhibitor may constitute a
good strategy for RA-associated endothelial dysfunction
is not known.
Besides the vasculature, a few studies investigated the
occurrence of arginase pathway abnormalities at the
articular level in RA and have yielded controversial
results. One study reported decreased arginase activity
in the synovial fluid of RA patients [17], whereas other
studies demonstrated increased arginase activity and
expression in the synovial fluid [18] as well as in plasma
[19]. Again, the pathophysiological role of arginase at
the articular level is still unknown, and whether arginase
inhibition might modify the severity of the disease has
never been investigated.
The aim of the present study was to determine the
effects of a curative treatment with Nw-hydroxy-nor-L-
arginine (nor-NOHA), a selective arginase inhibitor, in
AIA rats. The effect of nor-NOHA on vascular reactivity
to vasodilating and vasoconstrictive drugs was evaluated
on aortic rings, with special emphasis on the mechan-
isms involved in endothelial dysfunction. Additionally,
we assessed the impact of the treatment on clinical,
radiological and histological articular parameters as well
as on peripheral markers of inflammation and endothe-
lial function.
Materials and methods
Induction of AIA, clinical evaluation and treatment
A total of 48 male Lewis rats were purchased from Jan-
vier (Le Genest Saint Isle, France). Animals were kept
under a 12 h:12 h light:dark cycle and allowed free
access to food and water. The investigation conforms
with the Guide for the Care and Use of Laboratory Ani-
mal published by the US National Institutes of Health
(NIH publication No. 85-23, revised 1996) and was
approved by our local animal ethics committee.
Adjuvant arthritis was induced by a single intradermal
injection at the base of the tail of 1 mg of heat-killed
Mycobacterium butyricum (Difco, Detroit, MI, USA)
suspended in 0.1 ml of mineral oil (Freund’s incomplete
adjuvant (Difco). The animals developed arthritis
between Day 10 and Day 15. At the first symptoms of
arthritis, arthritic rats were randomly divided into two
groups: untreated AIA rats (n = 20) and nor-NOHA-
treated AIA rats (n = 20). Nor-NOHA (Bachem, France)
was dissolved in saline and administered once a day (40
mg/kg, ip) for 21 consecutive days. This inhibitor was
chosen because it is a potent selective arginase inhibitor
without interfering with NOS activity [20] or L-arginine
uptake [21]. Nor-NOHA inhibited arginase activity in
aorta with an IC50 of less than 1 μM, that is, similar to
its effects on liver arginase (IC50 = 0.5 μM). We pre-
viously demonstrated that the dose of 40 mg/kg/day was
well-tolerated and led to reduction of arginase I activity
(liver isoform, -41%) and arginase II activity (kidney iso-
form, -40%) [11], without any modification of plasma
urea levels [10]. Untreated AIA received an equal
volume of saline daily. With this protocol, the treatment
was performed during the secondary chronic phase of
AIA, that is, during the development of severe disease
and during the phase at which systemic inflammatory
markers are high [22-24]. A group of untreated non-
arthritic age-matched rats was used as controls (n = 8).
Rats were weighed and monitored seven days per
week in a blinded fashion for clinical signs of arthritis.
The scoring system was employed as follows [25]:
arthritis of one finger scores 0.1, weak and moderate
arthritis of one big joint (ankle or wrist) scores 0.5 and
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intense arthritis of one big joint scores 1. Tarsus and
ankle was considered as the same joint. Sum of joints
scores of four limbs leads to an arthritic score of maxi-
mum 6 to each rat. The ankle diameter was measured
with a digital caliper (Vernier Stainless, Guangxi, China).
Tissue preparation
Twenty-one days after the onset of arthritis, rats were
anaesthetized with pentobarbital (60 mg/kg, ip). Blood
was withdrawn from the abdominal aorta, immediately
centrifuged at 4,000 g for 10 minutes, and plasma was
stored at -80°C until analysis. Thoracic aortas were
removed, cleaned and immediately used for vascular
reactivity studies. Ankles were removed and placed in
4% formalin.
Vascular reactivity
Arthritis was induced in five rats per week so that the
onset of arthritis was shifted by one week for the differ-
ent groups. For one given rat, studies were performed
on both endothelium intact and endothelium denuded
rings, five days a week. For the experiments without
incubation of an inhibitor, the same ring was used for
different experiments. With this protocol, the study of
aortic vasodilator response was conducted over a 10-
week period. The thoracic aorta was excised, cleaned of
connective tissue and cut into rings of approximately 2
mm in length. Rings were suspended in Krebs solution
(NaCl 118 mmoles/liter, KCl 4.65 mmoles/liter, CaCl2
2.5 mmoles/liter, KH2PO4 1.18 mmoles/liter, NaHCO3
24.9 mmoles/liter, MgSO4 1.18 mmoles/liter, glucose 12
mmoles/liter, pH 7.4), maintained at 37°C and continu-
ously aerated with 95% O2, 5% CO2, for isometric ten-
sion recording in organs chambers, as previously
described [26]. In some rings, endothelium was
mechanically removed. The completeness of endothelial
denudation was confirmed by the absence of relaxation
to the endothelium-dependent agonist acetylcholine
(Ach, 10-6 moles/liter). After a 90-minute-equilibration
period under a resting tension of 2 g, rings with intact
endothelium were constricted with norepinephrine (NE,
3. 10-7 moles/liter) and endothelium-dependent relaxa-
tion was assessed with Ach (10-11-10-4 moles/liter). To
dissect the mechanisms of endothelial dysfunction, rings
were incubated for 30 minutes respectively with the
non-selective NO synthase inhibitor NW-nitro-L-argi-
nine methyl ester (L-NAME, 10-4 moles/liter), the selec-
tive inhibitor of inducible NOS (1400 W, 10-5 moles/
liter), the Ca2+-dependent K+ channels inhibitors apamin
(10-7 moles/liter) and charybdotoxin (10-7 moles/liter),
the non-selective COX inhibitor indometacin (10-5
moles/liter), the selective COX-2 inhibitor (NS398, 10-5
moles/liter), the prostacyclin (PGI2) synthase inhibitor
tranylcypromine (10-5 moles/liter), the thromboxane
(TX) synthase inhibitor furegrelate (10-6 moles/liter), the
superoxide dismutase mimetic (SOD) Tempol (10-4
moles/liter) and with the add of “respectively” above we
must let “and” the nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase inhibitor apocynin (3. 10-4
moles/liter). To determine the sensitivity of vascular
smooth muscle cells to physiological vasoconstrictive
factors, endothelium-denuded rings were constricted
with NE (10-11-10-4 moles/liter), ET-1 (10-10-10-6 moles/
liter) or ANG-II (10-10-10-6 moles/liter). Finally, we eval-
uated the endothelium-independent relaxation to the
NO donor sodium nitroprussiate (SNP, 10-11-10-4
moles/liter) after constriction with NE 3. 10-7 moles/
liter.
Plasma IL-6, IL-1b, TNFa and VEGF levels
Plasma levels of interleukin-6 (IL-6), interleukin-1b (IL-
1b) and tumor necrosis factor-alpha (TNFa), three per-
ipheral markers of inflammation and plasma concentra-
tion of the vascular endothelial growth factor (VEGF), a
peripheral marker of endothelial dysfunction in many
cardiovascular diseases [27,28], were determined by
using enzyme-linked immunosorbent assay (ELISA) kits
according to the manufacturer’s instructions (Bender
MedSystems, Vienna, Austria). The limits of detection
of ELISA kits provided by the manufacturer for TNF a,
IL-6, IL-1b and VEGF were 11.2 pg/mL, 12 pg/mL, 4
pg/mL and 27 pg/mL, respectively.
Radiographical ex vivo analysis of joints of ankle and foot
The high resolution digital X-rays (25 kV, 10 mA) of
hind paws of rats in three groups were performed with
a Nova Siemens Mammomat 3000 (Erlangen, Germany)
the city is Erlangen at Day 21 after the onset of inflam-
matory joint signs. A score of 0 to 3 was determined for
each paw, according to Du et al. [29]. This score takes
into account the swelling of soft parts, the thickness of
the joint space, bone destruction and the neoformation
of periosteal tissue, as follows: 0 = normal, 1 = soft tis-
sue swelling only, 2 = soft tissue swelling and early ero-
sions and 3 = severe erosions, the maximum score for
each rat being 6.
Histological analysis
Ankles were decalcified and embedded in paraffin and
sections of 6 μm were performed and stained with
hematoxylin-eosin and safranin (HES). The histological
features of cartilage, bone and periarticular soft tissue
were evaluated in a blind fashion by using the score of
Kinne et al. [30]. According to this score, the degree of
inflammatory infiltration is scored from 0 to 3 where 0
= no infiltration, 1 = slight infiltration, 2 = moderate
infiltration and 3 = severe infiltration. The degree of
bone and cartilage destruction is scored from 0 to 4,
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where 0 = no erosion of cartilage or bone, 1 = unequi-
vocal erosion ≤ 10% of cartilage or bone trabeculae, 2 =
erosions ≤ 50% 3 = erosions from 50 to 90% and 4 =
erosions > 90%. The maximum score per rat is 7.
Data and statistical analysis
Values are presented as the mean ± SEM. The values of
maximal relaxation (Emax values) were determined by
fitting the original dose-response curves using the Sigma
Plot program (Systat Software, Chicago, IL USA). The
curves obtained from aortic rings were compared by
two-way analysis of variance. Comparison between
groups was assessed by one-way analysis of variance
(ANOVA) followed by Bonferroni’s test. The analysis of
the relationship between two parameters was deter-
mined by linear regression analysis and Spearman’s cor-
relation coefficient was calculated between these
variables. P < 0.05 was considered statistically
significant.
Results
Arthritis severity was unaffected by nor-NOHA treatment
Body weights, ankle diameters and arthritis scores are
shown in Table 1. Compared to control rats, AIA rats
exhibited a significantly reduced body weight and a
higher ankle diameter. The nor-NOHA treatment did
not affect body weight, ankle diameter or arthritic score
in AIA rats. Nor-NOHA did not modify the time-course
of arthritic scores and did not delay the occurrence of
arthritis symptoms, as presented in more details in
Additional file 1. The radiological and histological analy-
sis of AIA rats showed bone and cartilage erosions with
joint space narrowing, inflammatory synovitis and
inflammatory infiltration of the soft parts that were
unaffected by nor-NOHA (Figure 1). Accordingly, the
histological and radiological scores of nor-NOHA-trea-
ted AIA rats were not different from those of untreated
AIA rats (Table 1).
Nor-NOHA treatment decreased IL-6 and VEGF plasma
levels in AIA rats
TNFa and IL-1b were not detectable in plasma what-
ever the group of rats (data not shown). IL-6 and VEGF
plasma levels were significantly higher in AIA rats as
compared to control rats (P < 0.05, Table 1). Nor-
NOHA significantly prevented the increase in IL-6 and
VEGF levels in AIA rats. A significant positive correla-
tion was found between VEGF and endothelial dysfunc-
tion as attested by the negative correlation identified
between the Emax of Ach and the plasma VEGF levels
(r = - 0.536, P = 0.007). Additional file 2 shows this in
more detail. By contrast, IL-6 levels did not correlate
with Emax of Ach (r = 0.001, P = 0.959, data not
shown).
Nor-NOHA treatment improved vascular function in AIA
rats
To confirm the presence of endothelial dysfunction in
AIA rats, we first investigated the vasodilatory response
of endothelium-intact rings to Ach. As shown in Figure
2A, as a reflection of endothelial dysfunction, the relax-
ant effect of Ach was significantly reduced in AIA rats
compared to control rats. Importantly, nor-NOHA treat-
ment totally reversed the impairment of Ach-induced
relaxation in AIA rats (Figure 2A). By contrast, no dif-
ference in SNP-induced vasorelaxation was observed
among control rats, untreated AIA and nor-NOHA-trea-
ted AIA rats (Figure 2B), thus confirming the normality
of the response of VSMC to exogenous NO, as pre-
viously reported [3]. To determine whether aortic rings
from AIA rats exhibited an altered response to physiolo-
gically-relevant vasoconstrictors, the effect of NE, ANG-
II and ET-1 was evaluated. As shown in Figures 2C-E,
the vasoconstrictive responses to NE, ANG-II and ET-1
were not different between the three groups of rats.
Overall results indicate that the impaired Ach-induced
vasorelaxation observed in AIA rats strictly resulted
from an impairment of endothelial production of relax-
ant factors.
To determine the mechanisms involved in the benefi-
cial effects of nor-NOHA treatment on endothelial func-
tion, we first investigated the contribution of the NOS
and EDHF pathways in Ach-induced vasorelaxation in
control and AIA rats. As shown in Figure 3, as a reflec-
tion of a NOS-activation after Ach challenge, L-NAME,
a non-selective NOS inhibitor, significantly reduced the
Ach-dependent relaxation in all experimental groups
(Figure 3A-C). However, the decrease in the Emax of
Ach was greater in controls and nor-NOHA-treated
Table 1 Clinical, histological and radiological scores and









Body weight (g) 310 ± 3 279 ±
10*
269 ± 5*
Arthritis score 0 1.3 ± 0.2* 1.1 ± 0.2*
Ankle diameter
(mm)
7.6 ± 0.1 8.3 ± 0.2* 8.3 ± 0.1*
Histological score 0 4.1 ± 3.7 ± 1*
Radiological score 0 2.2 ± 2.1 ± 0.6*
IL-6 (pg/ml) 366 ± 22 419 ±
17*
378 ± 22
VEGF (pg/ml) 488 ± 36 642 ±
34*
500 ± 65
Data were obtained 21 days after the onset of arthritis in control rats, AIA rats
and nor-NOHA treated rats. Values are the mean ± SEM. * = P <0.05 vs
control
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AIA rats (-45 ± 12% and -50 ± 6%, respectively) com-
pared to untreated AIA group (-32 ± 6%). This result
demonstrated that NOS activation is blunted in the case
of arthritis and restored after nor-NOHA treatment.
Conversely, the selective inducible NOS inhibitor 1400
W did not affect the response to Ach, whatever the
group (data not shown). Because the role of EDHF is of
critical importance for endothelial function, when NO
production is compromised [31], we investigated the
 
 
Figure 1 Radiographs and histological aspect of hind limbs at Day 21 after the onset of arthritis. Experiments were performed in
controls rats (A, D), AIA rats (B, E) and nor-NOHA treated rats (C, F). On radiographs, both AIA and treated AIA rats exhibited a thickening of the
soft tissues of the ankle and foot as well as a joint destruction and periosteal tissue neoformation. Histological slices were stained with HES
(enlargement × 20). A severe joint destruction associated to synovial proliferation was present in AIA and treated AIA rats.
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Figure 2 Vascular reactivity to vasodilators and
vasoconstrictive agents. Experiments were performed on thoracic
aortic rings from control rats, AIA rats and nor-NOHA AIA rats 21
days after the onset of arthritis. A, Concentration - response curve
for Ach in endothelium-intact rings preconstricted with NE 3 × 10-7
moles/liter. B, Concentration - response curve for SNP in
endothelium-denuded rings preconstricted with NE 3 × 10-7 moles/
liter. C, Concentration - response curve for NE in endothelium-
denuded rings, D, Concentration - response curve for ANG-II in
endothelium-denuded rings, E, Concentration - response curve for
ET-1 in endothelium-denuded rings. Values are the mean ± SEM
from 8 to 12 rings. * = P < 0.05. KKCl = Krebs potassium chloride
solution.
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Figure 3 Effect of L-NAME and the combination of apamin/
charybdotoxin on vasodilation response to Ach. Experiments
were performed on aortic rings isolated from control rats (A, D), AIA
rats (B, E) and nor-NOHA AIA rats (C, F) 21 days after the onset of
arthritis. Cumulative concentration-responses curves with Ach were
obtained after a 60-minute incubation period with L-NAME at 10-4
moles/liter (A, B, C) or with apamin-charybdotoxin at 10-7 moles/liter
each (D, E, F). Values are the mean ± SEM from 8 to 12 rings. * = P
< 0.05, *** = P < 0.001.
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effect of nor-NOHA on EDHF production by incubating
the rings with apamin and charybdotoxin. In favor of
decreased EDHF production in arthritis, the combina-
tion of apamin/charybdotoxin significantly decreased the
effect of Ach in control rats (Figure 3D) but not in AIA
rats (Figure 3E) suggesting that the EDHF-mediated
compensatory vasodilator system is lacking in arthritis.
Nor-NOHA fully restored the EDHF component of
Ach-induced relaxation in AIA rats (Figure 3F). To
determine the role of prostanoids in endothelial dys-
function in AIA, aortic rings were first incubated with
the non-selective COX inhibitor indometacin. While
indometacin did not modify the relaxation to Ach in the
control group (Figure 4A), it significantly improved
vasodilation in untreated AIA rats (Figure 4B), indicat-
ing a deleterious role of COX activation in arthritis-
induced endothelial dysfunction. More precisely, as a
reflection of a deleterious role of the overactivation of
COX-2, TX synthase and PGI2 synthase in endothelial
dysfunction, the same patterns were observed after incu-
bation with NS398 (Figure 4A), furegrelate and tranylcy-
promine, respectively, in controls (Figure 4B) and in
AIA rats (Figure 4C, D). The treatment with nor-NOHA
normalized the effect of these prostanoids inhibitors to
that of control rats (Figures 4E, F).
To assess whether the beneficial effects of nor-NOHA
were linked to a decrease in O2
-. production in the
aorta, rings were incubated with the SOD mimetic Tem-
pol and with the NADPH oxidase inhibitor apocynin.
Although neither Tempol nor apocynin altered relaxa-
tion to Ach in control group (Figure 5A, B), they signifi-
cantly improved vasodilation in untreated AIA rats
(Figure 5C, D), thus indicating that overproduction of
O2
-. as well as overactivation of NADPH oxidase contri-
bute to endothelial dysfunction in arthritis, as previously
demonstrated [4]. After treatment with nor-NOHA, the
Ach-induced relaxation remained unaffected by both
compounds suggesting a normalization of O2
-. produc-
tion and NADPH oxidase activity (Figure 5E, F).
Discussion
Regarding how important is the prevention of cardiovas-
cular events in RA, the understanding of the mechan-
isms associated to endothelial dysfunction, as well as the
identification of new relevant treatments are of particu-
lar importance. The present study investigated for the
first time the effect of a curative treatment with an argi-
nase inhibitor (nor-NOHA) on vascular function of AIA
rats. Our results demonstrated that this treatment
improves endothelial function via an increase in NOS
Log Ach (moles/liter)

































































































































































































Figure 4 Effect of indometacin, NS398, furegrelate and
tranylcypromin on vasodilation response to Ach. Cumulative
concentration curves were obtained in aortic rings isolated from
AIA, nor-NOHA AIA and control rats 21 days after the onset of
arthritis. Cumulative concentration curves with Ach were obtained
after a 60-minute incubation period with indometacin at 10-5
moles/liter or with NS398 at 10-4 moles/liter in controls (A), AIA (C)
and nor-NOHA AIA (E) or with furegrelate at 10-6 moles/liter or with
tranylcypromine at 10-5 moles/liter in controls (B), AIA (D) and nor-
NOHA AIA (F). Values are the mean ± SEM from 8 to 12 aortic rings.
* = P <0.05.
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Figure 5 Effect of Tempol and apocynin on vasodilation
response to ACh. Experiments were performed on aortic rings
isolated from control rats (A, B), AIA rats (C, D) and nor-NOHA AIA
rats (E, F) 21 days after the onset of arthritis. Cumulative
concentration-responses curves with Ach were obtained after a 60-
minute incubation period with Tempol at 10-4 moles/liter (A, C, E)
or with apocynin at 3 × 10-4 moles/liter (B, D, F). Values are the
mean ± SEM from 8 to 12 rings. ** = P < 0.01.
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activity and EDHF production, a decrease in COX-2, TX
synthase and PGI2 synthase activities as well as a
decrease in O2
-. production. However, our data did not
argue for a role of arginase in the chronic phase of
inflammatory joint damages in the AIA model.
In accordance with previous studies [3-5,32-34], our
data showed impaired endothelial function in AIA rats.
To ascertain that the abnormal response of vessels from
AIA rats to Ach was not due to decreased response of
vascular smooth muscle cells (VSMCs) to NO, we
demonstrated that the relaxing effect of the NO donor
SNP is not impaired in AIA rats, in agreement with
recent studies in rats [4,6,35] as well as in RA patients
[36-38]. Likewise, to eliminate the contribution of an
abnormal response of VSMCs to endothelium-derived
vasoconstrictive mediators, we demonstrated that the
effects of NE, ANG-II and ET-1 are unaltered in AIA
rats. To understand the mechanisms involved in the
effects of nor-NOHA, and because arginase and
endothelial NOS share the same substrate L-arginine,
aortic rings were first incubated with the non-selective
NOS inhibitor L-NAME. Our data showed that the
treatment with nor-NOHA significantly restored the
decreased NOS activity observed in AIA rats. This result
argues for the contribution of increased vascular argi-
nase activity to NO deficiency in AIA rats, and demon-
strated that in vivo arginase inhibition restores the
equilibrium between NOS and arginase pathways, as
previously identified in animal models of cardiovascular
diseases, such as hypertension [10,11], atherosclerosis
[13] or ageing [14]. Another new finding is the lack of
effect of the selective iNOS inhibitor 1400 W on
endothelial dysfunction in AIA. Data on vascular iNOS
expression in AIA are controversial since the expression
was found to be unchanged [4] or increased [35]. Our
data showing the lack of effect of 1400 W on Ach-
induced vasodilation, whatever the group of rats, did not
argue for a contribution of the iNOS pathway in the
impaired endothelial function associated to RA. This
result contrasts with that of a study conducted in a
small cohort of RA patients suggesting a deleterious role
of increased vascular iNOS expression in vascular dys-
function [36]. However, in this study, the iNOS inhibitor
used was aminoguanidine, which has a wide range of
pharmacological actions besides iNOS inhibition includ-
ing antioxidant effects [39], and it cannot be excluded
that this latter property accounted for its vascular effect.
Collectively, these data emphasize the need for further
studies to define the role of iNOS in RA-associated
endothelial dysfunction.
The COX pathway plays an important role in
endothelial function. COX-1 is expressed constitutively
and is usually abundant in all animal and human
endothelial cells, whereas endothelial COX-2 is induced
mainly during inflammatory response [40]. Physiologi-
cally, COX synthesizes both vasorelaxant prostanoids,
such as PGI2 and vasoconstrictive prostanoids, such as
TXA2. On the basis of the effects observed for indome-
tacin and the preferential COX-2 inhibitor NS-398, the
present study demonstrates for the first time that COX-
2 activation contributes to endothelial dysfunction in
aorta of AIA rats. Our result is consistent with the
results of a recent study showing that vascular COX-2
expression was overexpressed in rabbits with both
chronic AIA and atherosclerosis [41]. Although the con-
tribution of COX-2 and TX synthase overactivation to
endothelial dysfunction has been already demonstrated
in animal models of cardiovascular diseases [40], the
negative role of PGI2 is more surprising. In fact, our
results confirm the janus face of PGI2 and suggest that,
as described in spontaneously hypertensive rats (SHR)
[42], PGI2 can induce vasoconstriction in AIA rats.
Importantly, nor-NOHA treatment totally normalized
the COX-pathway dysfunction in AIA rats. These data
are in accordance with a previous study conducted in
SHR in which nor-NOHA treatment was able to
improve the COX-dependent component of Ach by
decreasing vascular COX-2 expression [11].
Despite the ongoing debate of the molecular identity
and signalling pathways, the contribution of endothe-
lium-derived hyperpolarizing factor(s) (EDHFs) to the
endothelium-dependent relaxation is also considered as
an important feature of normal endothelium function
[31]. EDHF has been demonstrated unequivocally in var-
ious blood vessels from different species, including
human [43]. The acronym ‘EDHF’ is applied to a factor
inducing vascular relaxation in the presence of COX
plus NOS inhibitors and which is inhibited by charybdo-
toxin + apamin but unaffected by iberiotoxin + apamin.
Animal studies have identified several mediators that
might act as EDHF, such as K+, cytochrome P450 meta-
bolites, lipoxygenase products, NO itself, H2O2, cyclic
adenosine monophosphate, C-type natriuretic peptide
and electrical coupling through myoendothelial gap
junctions [43,44]. Whatever the mediator, EDHF induces
a potassium-mediated event associated to a reduction in
intracellular K+ in vascular smooth muscle [45]. Experi-
mental evidence indicates that EDHF action is of critical
importance for endothelial function when NO produc-
tion is compromised [31]. Our data showed for the first
time that EDHF production is impaired in AIA rats,
suggesting that the EDHF-mediated compensatory dila-
tor system is lacking in RA. Of interest, our data
reported that arginase inhibition restored the EDHF
contribution to that of control rats. Because of the exis-
tence of a cross-talk between NO and EDHF pathways
[31], it can be hypothesized that the improvement of
NO production by nor-NOHA contributes to the
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recovery of EDHF production in AIA treated rats. How-
ever, albeit non-elucidated, a direct effect of nor-NOHA
on EDHF production cannot be excluded.
Previous reports suggested that the overproduction of
O2
-. contributes to endothelial dysfunction in AIA rats
[4,5]. Consistent with these findings, the present study
demonstrates the improvement of ACh-induced vasore-
laxation with a SOD mimetic. In the AIA model, pre-
vious data reported that statins [5] as well as ANG-II
receptor antagonists [6] were able to decrease aortic O2
-.
overproduction. In the present study, we provide evi-
dence that this beneficial effect can also be obtained
with an arginase inhibitor. It is worth noting that recent
reports reported that statins inhibit arginase activity
[46,47] and that blockade of ANG-II AT1 receptors pre-
vents the ANG II-induced elevation of arginase activity
and expression [48]. Although speculative, we hypothe-
size that arginase could be the downstream common
effector of these two types of drugs. Because the defi-
ciency of L-arginine causes a NOS uncoupling leading
to O2
-. production [40], the beneficial effect of arginase
inhibition on O2
-. production might be due to the
decrease in vascular eNOS uncoupling, as recently
demonstrated in the vasculature of aged rats treated
with the arginase inhibitor 2S-amino-6-boronohexanoic
acid [49]. Additionally, since COX-2 was found to con-
tribute to O2
- production [40], the nor-NOHA-induced
decrease in COX-2 activity might also contribute to this
effect. Moreover, our results confirmed the deleterious
impact of increased NADPH oxidase activity to
endothelial function in AIA [4] and demonstrated that
nor-NOHA reverses this phenomenon. Whether argi-
nase inhibition can directly reduce NADPH oxidase
activity/expression is currently unknown but a recent
study showing that NADPH oxidase inhibition reduced
arginase upregulation in retinal cells [50] suggests an
interplay between the two enzymes.
Although there is now ample evidence that RA is
associated with endothelial dysfunction [1], several
issues remain unresolved concerning the potential con-
tribution of disease activity and classical cardiovascular
risk factors. In addition, whether endothelial dysfunction
occurs before the onset of RA or is a consequence of
the disease is still a matter of debate. The presence of
endothelial dysfunction in the very early stages of RA
was recently demonstrated and was not explained by
differences in disease activity and inflammatory markers
[51]. Conversely, no impairment of endothelial function
was observed in patients with < 7 years’ disease duration
whereas longer disease duration (> 14 years) was asso-
ciated with severe endothelial dysfunction [52]. Others
showed that endothelial dysfunction reflects enhanced
inflammatory disease activity [38,53]. Moreover, on the
observation that elevated inflammatory molecules are
associated with increased risk of cardiovascular diseases
in the general population, it has been speculated that
RA-related inflammation might contribute to endothelial
dysfunction [1]. However, as emphasized in a recent
review [1], there is surprisingly no direct evidence sup-
porting such an association between systemic inflamma-
tion and vascular dysfunction in RA patients. Therefore,
two hypotheses might be formulated to explain how a
treatment can improve endothelial function in RA. First,
the benefits might be secondary to decreased systemic
and/or vascular inflammation and disease activity. Sec-
ond, the treatment may act directly on endothelial
homeostasis independently of inflammation or disease
activity. In our study, we showed that nor-NOHA treat-
ment did not modify disease severity assessed by clinical,
histological and radiological parameters, whereas it fully
reversed endothelial dysfunction in AIA rats. These
results demonstrate that the reduction of endothelial
dysfunction is possible even though articular parameters
are not improved and that endothelial dysfunction is not
the consequence of the disease, at least in the chronic
phase of the AIA model. These data are in keeping with
a recent report showing that an angiotensin-converting
enzyme (ACE) inhibitor improved endothelial dysfunc-
tion without any change in disease activity in RA
patients [54]. In this study, treatment with ramipril
markedly improved endothelial function, although it
modestly reduced circulating cytokines, indicating that
other mechanisms than the reduction of vascular
inflammation are likely involved in the beneficial effects
of the ACE inhibitor. Likewise, our data showing that
plasma IL-6 levels did not correlate with endothelial
dysfunction strongly suggest that the benefits provided
by nor-NOHA are related to the direct modulation of
endothelium-derived vasorelaxant pathways rather than
an anti-inflammatory effect. In addition, our data also
suggest that arginase is not upregulated at the articular
level and/or not involved in the evolution of the disease
between the Day 13 and the Day 34 post-immunization,
that is, during the chronic phase of AIA. These data are
in agreement with a recent study conducted on arthritic
mice showing that arginase gene expression in synovial
tissue increased during acute inflammation but not dur-
ing chronic inflammation [55]. Further studies will be
necessary to explore the role of arginase at the articular
level in RA.
With the aim to identify clinically relevant peripheral
markers of endothelial dysfunction in RA, we measured
plasma VEGF levels in control and AIA rats. Although
increased VEGF level is considered as a marker of
endothelial dysfunction in hypercholesterolemia, athero-
sclerosis or hypertension [28], whether VEGF is a mar-
ker of endothelial dysfunction in RA is not known.
Previous studies conducted in RA patients reported
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elevated VEGF levels in serum, which were related to
angiogenesis of synovial pannus but not with endothelial
dysfunction [56]. In the present study, we showed that
VEGF levels are increased in AIA rats, and that nor-
NOHA treatment decreased VEGF levels, whereas
arthritis severity was unchanged. Importantly, we identi-
fied the existence of a negative correlation between
VEGF levels and endothelial function, suggesting for the
first time that high plasma VEGF levels might reflect
endothelial dysfunction in RA. The mechanisms explain-
ing the decrease in VEGF levels after arginase inhibition
were not determined in the present study but might rely
on decreased IL-6 production since VEGF synthesis is
IL-6 dependent [57].
Conclusions
In conclusion, the present study on AIA rats gives
important new data for the management of endothelial
dysfunction in RA. First, it identifies decreased EDHF
production and increased COX-2 activity as new patho-
physiological mechanisms of endothelial dysfunction
besides decreased NOS activity and O2
-. overproduction,
thus providing new potential targets for the treatment
of this cardiovascular risk factor in RA. Second, it
demonstrates that the treatment with an arginase inhibi-
tor is a promising and efficient approach for reversing
endothelial dysfunction in RA, as originally suggested in
animal models of “traditional” cardiovascular diseases
[58]. Although these data obtained in AIA rats have to
be confirmed by clinical studies, our data strongly sug-
gest that arginase inhibition has the potential as a novel
add-on therapy in the treatment of RA.
Additional material
Additional file 1: Time-course of clinical arthritic score in AIA and
nor-NOHA-treated AIA rats. AIA rats were monitored seven days per
week in a blinded fashion for clinical signs of arthritis. Day 0 = day of
injection with Mycobacterium butyricum. The nor-NOHA treatment was
started with the first clinical signs of arthritis. n = 20 rats per group. NS,
Non-significant.
Additional file 2: Regression analysis between plasma VEGF and
endothelial dysfunction. A significant positive correlation was found
between plasma VEGF levels and endothelial dysfunction as attested by
the negative correlation identified between the Emax of Ach and the
plasma VEGF levels of control, AIA and nor-NOHA-treated AIA rats (n = 8
rats per group).
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